SG10201804330YA - Engineered high-affinity human t cell receptors - Google Patents
Engineered high-affinity human t cell receptorsInfo
- Publication number
- SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA
- Authority
- SG
- Singapore
- Prior art keywords
- tcrs
- cell receptors
- affinity
- affinity human
- engineered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907887P | 2013-11-22 | 2013-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804330YA true SG10201804330YA (en) | 2018-07-30 |
Family
ID=53180203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804330YA SG10201804330YA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10023625B2 (es) |
| EP (2) | EP3071593B1 (es) |
| JP (4) | JP6697386B2 (es) |
| KR (2) | KR102415259B1 (es) |
| CN (2) | CN105873945B (es) |
| AU (4) | AU2014352834B2 (es) |
| BR (1) | BR112016011567A2 (es) |
| CA (2) | CA2930847A1 (es) |
| DK (1) | DK3071593T3 (es) |
| ES (1) | ES2729406T3 (es) |
| IL (2) | IL245468B (es) |
| MX (3) | MX371202B (es) |
| PL (1) | PL3071593T3 (es) |
| PT (1) | PT3071593T (es) |
| RU (2) | RU2729383C2 (es) |
| SA (1) | SA516371174B1 (es) |
| SG (2) | SG10201804330YA (es) |
| TR (1) | TR201908404T4 (es) |
| WO (2) | WO2015077615A1 (es) |
| ZA (2) | ZA201603116B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009511637A (ja) | 2005-10-17 | 2009-03-19 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法 |
| EP3834836A1 (en) | 2006-04-10 | 2021-06-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and uses thereof |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| AU2014207615B2 (en) | 2013-01-15 | 2018-11-01 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| TR201908404T4 (tr) * | 2013-11-22 | 2019-07-22 | Hutchinson Fred Cancer Res | İşlenmiş yüksek afinite insan t hücresi reseptörleri. |
| EA201890772A1 (ru) * | 2015-09-22 | 2018-10-31 | Юлиус Максимилианс-Универзитет Вюрцбург | Способ высокоуровневого и стабильного переноса генов в лимфоцитах |
| CN108290940B (zh) * | 2015-10-01 | 2021-12-07 | 圣拉斐尔医院有限公司 | Tcr及其用途 |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| US11026969B2 (en) | 2015-12-23 | 2021-06-08 | Fred Hutchinson Cancer Research Center | High affinity T cell receptors and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| RU2019116312A (ru) | 2016-11-14 | 2020-12-14 | Фред Хатчинсон Кэнсер Рисерч Сентер | Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения |
| SG11201908527SA (en) * | 2017-03-15 | 2019-10-30 | Hutchinson Fred Cancer Res | High affinity mage-a1-specific tcrs and uses thereof |
| EA201992536A1 (ru) * | 2017-04-24 | 2020-03-05 | Оспедале Сан Раффаэле С.Р.Л. | Tcr и пептиды |
| JP7181517B2 (ja) * | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| CA3107019A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| WO2021034976A1 (en) * | 2019-08-20 | 2021-02-25 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
| MX2022009815A (es) * | 2020-02-12 | 2022-10-28 | Abbvie Inc | Moleculas de union biespecificas. |
| IL297594A (en) | 2020-04-28 | 2022-12-01 | Achilles Therapeutics Uk Ltd | t cell therapy |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| KR20240023426A (ko) | 2021-06-22 | 2024-02-21 | 아킬레스 테라퓨틱스 유케이 리미티드 | 항원-특이적 t 세포를 생산하는 방법 |
| KR20240046834A (ko) * | 2021-07-19 | 2024-04-09 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fanci, rad51, 및 pbk 항원을 표적화하는 펩타이드 및 가공된 t 세포 수용체 및 이의 사용 방법 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4640561A (en) | 1985-11-15 | 1987-02-03 | Ford Motor Company | Flexible printed circuit connector |
| US5059413A (en) | 1988-04-18 | 1991-10-22 | Xoma Corporation | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5299253A (en) | 1992-04-10 | 1994-03-29 | Akzo N.V. | Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| EP1066380B1 (en) | 1998-05-19 | 2001-11-14 | Avidex Ltd | Soluble t cell receptor |
| ES2293748T3 (es) | 1998-10-21 | 2008-03-16 | Altor Bioscience Corporation | Moleculas de fijacion poliespecificas y usos de las mismas. |
| MXPA04001974A (es) | 2001-08-31 | 2004-07-16 | Avidex Ltd | Receptor de celula t soluble. |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| DE602005011617D1 (de) | 2004-05-19 | 2009-01-22 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| DE602005009825D1 (de) | 2004-05-19 | 2008-10-30 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
| GB0524477D0 (en) * | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| CA2743669C (en) * | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| WO2010075417A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| AU2010210083C1 (en) | 2009-02-09 | 2015-11-26 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| MX2013000989A (es) | 2010-07-28 | 2013-03-05 | Immunocore Ltd | Receptores de celulas t. |
| RS56339B1 (sr) | 2010-09-20 | 2017-12-29 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t ćelijski receptori i t ćelijski epitopi |
| JP6251734B2 (ja) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | 親和性増強型ｔ細胞受容体およびその作製方法 |
| WO2014191465A1 (en) * | 2013-05-28 | 2014-12-04 | Møller Niels Iversen | Peptides derived from lawsonia intracellularis and their use in vaccination |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| TR201908404T4 (tr) | 2013-11-22 | 2019-07-22 | Hutchinson Fred Cancer Res | İşlenmiş yüksek afinite insan t hücresi reseptörleri. |
| ES2841274T3 (es) | 2014-08-04 | 2021-07-07 | Hutchinson Fred Cancer Res | Inmunoterapia con células T específica para WT-1 |
-
2014
- 2014-11-21 TR TR2019/08404T patent/TR201908404T4/tr unknown
- 2014-11-21 JP JP2016533163A patent/JP6697386B2/ja not_active Expired - Fee Related
- 2014-11-21 ES ES14863490T patent/ES2729406T3/es active Active
- 2014-11-21 MX MX2016006620A patent/MX371202B/es active IP Right Grant
- 2014-11-21 DK DK14863490.0T patent/DK3071593T3/da active
- 2014-11-21 BR BR112016011567A patent/BR112016011567A2/pt not_active Application Discontinuation
- 2014-11-21 AU AU2014352834A patent/AU2014352834B2/en not_active Ceased
- 2014-11-21 US US15/037,476 patent/US10023625B2/en active Active
- 2014-11-21 AU AU2014352826A patent/AU2014352826B2/en active Active
- 2014-11-21 EP EP14863490.0A patent/EP3071593B1/en active Active
- 2014-11-21 KR KR1020167016131A patent/KR102415259B1/ko active IP Right Grant
- 2014-11-21 CA CA2930847A patent/CA2930847A1/en not_active Abandoned
- 2014-11-21 WO PCT/US2014/066903 patent/WO2015077615A1/en active Application Filing
- 2014-11-21 KR KR1020167016132A patent/KR20160085345A/ko not_active Application Discontinuation
- 2014-11-21 RU RU2016124163A patent/RU2729383C2/ru active
- 2014-11-21 PT PT14863490T patent/PT3071593T/pt unknown
- 2014-11-21 WO PCT/US2014/066892 patent/WO2015077607A1/en active Application Filing
- 2014-11-21 CA CA2930852A patent/CA2930852C/en active Active
- 2014-11-21 PL PL14863490T patent/PL3071593T3/pl unknown
- 2014-11-21 SG SG10201804330YA patent/SG10201804330YA/en unknown
- 2014-11-21 EP EP14864079.0A patent/EP3071594A4/en active Pending
- 2014-11-21 CN CN201480071620.2A patent/CN105873945B/zh active Active
- 2014-11-21 RU RU2016124179A patent/RU2740648C2/ru active
- 2014-11-21 CN CN201480071635.9A patent/CN105899530B/zh not_active Expired - Fee Related
- 2014-11-21 MX MX2016006625A patent/MX2016006625A/es unknown
- 2014-11-21 US US15/037,485 patent/US10344075B2/en active Active
- 2014-11-21 SG SG10201804335QA patent/SG10201804335QA/en unknown
- 2014-11-21 JP JP2016533150A patent/JP6476182B2/ja active Active
-
2016
- 2016-05-04 IL IL245468A patent/IL245468B/en active IP Right Grant
- 2016-05-04 IL IL245467A patent/IL245467B/en not_active IP Right Cessation
- 2016-05-10 ZA ZA2016/03116A patent/ZA201603116B/en unknown
- 2016-05-11 ZA ZA2016/03169A patent/ZA201603169B/en unknown
- 2016-05-20 MX MX2021006932A patent/MX2021006932A/es unknown
- 2016-05-21 SA SA516371174A patent/SA516371174B1/ar unknown
-
2018
- 2018-05-25 US US15/990,524 patent/US20190055298A1/en not_active Abandoned
-
2019
- 2019-10-17 JP JP2019190139A patent/JP6970724B2/ja active Active
- 2019-11-28 AU AU2019272003A patent/AU2019272003B2/en not_active Ceased
-
2021
- 2021-04-15 AU AU2021202274A patent/AU2021202274A1/en not_active Abandoned
- 2021-11-01 JP JP2021178468A patent/JP2022023196A/ja active Pending
-
2022
- 2022-01-27 US US17/586,652 patent/US20220396606A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201804330YA (en) | Engineered high-affinity human t cell receptors | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| CY1123142T1 (el) | Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων | |
| PH12019502529A1 (en) | Materials and methods for engineering cells and uses thereof in immuno-oncology | |
| NZ765695A (en) | Immune cell organoid co-cultures | |
| MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
| MX2019008346A (es) | Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos. | |
| MX2019013498A (es) | Receptor de antigeno quimerico y metodos para usarlo. | |
| PH12016500395A1 (en) | Cell penetrating conjugates and methods of use thereof | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| EP4279579A3 (en) | Methods and compositions for natural killer cells | |
| IN2014DN09787A (es) | ||
| MX2013008850A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX2019012017A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| MX2014014337A (es) | Metodo de produccion de alta concentracion de celulas madre. | |
| WO2012021632A3 (en) | Generation and use of pluripotent stem cells | |
| AU2016335217A8 (en) | Antigen receptors and uses thereof | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| IN2015KN00329A (es) | ||
| CY1123467T1 (el) | Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1 | |
| EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same |